If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
=== Exercise-induced regulation of genes in muscles === Gene expression in muscle is largely regulated, as in tissues generally, by regulatory DNA sequences, especially enhancers. Enhancers are non-coding sequences in the genome that activate the expression of distant target genes, by looping around and interacting with the promoters of their target genes (see Figure "Regulation of transcription in mammals"). As reported by Williams et al., the average distance in the loop between the connected enhancers and promoters of genes is 239,000 nucleotide bases.
=== United States === In 2014, the United States Food and Drug Administration (FDA) banned the import of kratom into the U.S. due to a lack of evidence for its safety. As of 2026, kratom is illegal in ten states: Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Rhode Island, Vermont, Massachusetts, and Wisconsin, and it may be outlawed by local ordinance in other states. As of early 2026, the states of Iowa, Nebraska, and South Dakota introduced bills with legislation that would ban kratom, while Iowa and Nebraska would also classify kratom as a Schedule I drug. In 2025, it both kratom and synthetic kratom were banned in the state of Massachusetts. December 2025, Ohio temporarily banned kratom-related products for 180 days, with the Ohio Board of Pharmacy moving toward a permanent ban on all forms of kratom by mid-2026. In late 2025, California Governor Gavin Newsom's administration began warning retailers that it is illegal to sell or manufacture kratom, which led to Los Angeles County banning kratom and Orange County significantly restricting kratom by banning synthetic or concentrated kratom products containing more than 2% 7-hydroxymitragynine. In 2016, kratom was banned in San Diego and Oceanside in California. In late 2017, there was consideration to make kratom a Schedule I drug. In June 2018, the US House passed the Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act. It was introduced in the Senate and referred to the Judiciary Committee, but no further action was taken.
The United States is well known for its theater. Mainstream theater in the United States derives from the old European theatrical tradition and has been heavily influenced by the British theater. By the middle of the 19th century, America had created new distinct dramatic forms in the Tom Shows, the showboat theater and the minstrel show. The central hub of the American theater scene is the Theater District in Manhattan, with its divisions of Broadway, off-Broadway, and off-off-Broadway. Many movie and television celebrities have gotten their big break working in New York productions. Outside New York City, many cities have professional regional or resident theater companies that produce their own seasons. The biggest-budget theatrical productions are musicals. U.S. theater has an active community theater culture. The Tony Awards recognize excellence in live Broadway theater and are presented at an annual ceremony in Manhattan. The awards are given for Broadway productions and performances. One is also given for regional theater.
== Collision cell technology with kinetic energy discrimination == Thermo Scientific's XSeries2 instrument utilizes a collision/reaction cell for interference removal, consisting of a non-consumable hexapole and chicane ion deflector, which takes the ion beam off-axis and leads to low instrument backgrounds of <0.5 integrated counts per second (icps) at vacant masses such as 5 and 220. This hexapole is inherently part of the Thermo lens system and is present in the ion path, regardless of the use of the collision cell. The collision/reaction gas mixtures can be 1% NH3 in He, 7% H2 in He and 100% H2, where the NH3 and H2 are reactive gasses and the He is a collisional gas. The 3rd generation cell utilizes kinetic energy discrimination, which employs running the quadrupole bias slightly less negative (more positive) than the hexapole bias. Polyatomic ions generated within the plasma can have larger atomic radii than analyte ions of similar mass, i.e. the interferent NaAr+ (mass 63) is larger than the analyte Cu+ (mass 63). Thus, when using a collisional/reactive gas mixture, these larger species undergo more collisions/reactions in the cell, in which they lose increasingly more energy, and are then excluded from the quadrupole mass filter by the kinetic energy barrier.
, not all individuals of the population have been removed, so some must remain susceptible. A driving force leading to the end of an epidemic is a decline in the number of infectious individuals. The epidemic does not typically end because of a complete lack of susceptible individuals. The role of both the basic reproduction number and the initial susceptibility are extremely important. In fact, upon rewriting the equation for infectious individuals as follows:
Sources: en.wikipedia.org
Wadden, Thomas A.; Chao, Ariana M.; Machineni, Sriram; Kushner, Robert; Ard, Jamy; Srivastava, Gitanjali; Halpern, Bruno; Zhang, Shuyu; Chen, Jiaxun; Bunck, Mathijs C.; Ahmad, Nadia N.; Forrester, Tammy (2023). "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial". Nature Medicine. 29 (11): 2909–2918. doi:10.1038/s41591-023-02597-w. PMC 10667099. PMID 37840095. Wadden, Thomas A.; Chao, Ariana M.; Moore, Molly; Tronieri, Jena S.; Gilden, Adam; Amaro, Anastassia; Leonard, Sharon; Jakicic, John M. (2023). "The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities". Current Obesity Reports. 12 (4): 453–473. doi:10.1007/s13679-023-00534-z. PMC 10748770. PMID 38041774. Wadden, Thomas A.; Brown, Gregory K.; Egebjerg, Christina; Frenkel, Ofir; Goldman, Bryan; Kushner, Robert F.; McGowan, Barbara; Overvad, Maria; Fink-Jensen, Anders (2024). "Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology". JAMA Internal Medicine. 184 (11): 1290–1300. doi:10.1001/jamainternmed.2024.4346. PMC 11372653. PMID 39226070.
=== Chemical labeling === Chemical labeling or the use of chemical tags utilizes the interaction between a small molecule and a specific genetic amino acid sequence. Chemical labeling is sometimes used as an alternative for GFP. Synthetic proteins that function as fluorescent probes are smaller than GFP's, and therefore can function as probes in a wider variety of situations. Moreover, they offer a wider range of colors and photochemical properties. With recent advancements in chemical labeling, Chemical tags are preferred over fluorescent proteins due to the architectural and size limitations of the fluorescent protein's characteristic β-barrel. Alterations of fluorescent proteins would lead to loss of fluorescent properties.
A number of security incidents are reported in London, Gatwick Airport and Chester, involving evacuations and anti-terror police. Queen Camilla misses the Royal Variety Performance because of "lingering post-viral" symptoms from her chest infection. 23 November The Ministry of Justice says it is aware of a data breach after details of the layouts of prisons in England and Wales were leaked to the dark web. Kensington Palace announces that the Princess of Wales has invited the families affected by the 2024 Southport stabbing to her annual Christmas carol service. It is reported that Andy Murray will coach his long-time former rival Novak Djokovic at the 2025 Australian Open. Less than five months after Labour won the 2024 general election, an online parliament petition calling for a new general election is launched and receives 200,000 signatures within its first six hours. 23–24 November – A number of yellow weather warnings for high winds and heavy rain are in place for Scotland, Northern Ireland, north Wales and northern England as Storm Bert arrives in the UK; there is also an amber alert for snow and ice in central Scotland. 24 November BBC News reports that businessman David Crisp, who was recorded telling an undercover reporter he was illegally selling luxury perfume to Russia, will not face criminal charges. An eight-year-old girl and a 34-year-old man are seriously injured in a shooting in Ladbroke Grove, West London. A 22-year-old man is arrested the following day on suspicion of attempted murder.
== Education and academic career == Bhushan began his education in his native India, completing his undergraduate and master's degrees from the University of Jodhpur. He received his Ph.D. in chemistry (working on structure elucidation of natural products isolated from certain desert plants) in 1978 at the University of Jodhpur. Bhushan joined as a lecturer at the University of Roorkee (now Indian Institute of Technology Roorkee, India) in 1979 and was later selected for the position of full professor of chemistry in 1996 and served there till retirement in 2018.
The Crick Papers at the Wellcome Trust. "Quiet debut for the double helix" by Professor Robert Olby, Nature 421 (23 January 2003): 402–405. Reading list for discovery of DNA story from the National Centre for Biotechnology Education. Papers of Francis Crick, 1953–1969 held at Churchill Archives Centre About his life
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.